Ranbaxy launches generic anti-ulcer drug

Ranbaxy has launched generic versions of Astrazeneca’s anti-ulcer drug Prilosec 40 mg in the US. Following a settlement in April, Astrazeneca made Ranbaxy the authorized generics partner, which means that the Indian company can sell its generic drugs for 180 days before Prilosec’s patent expires.

However, the US-based company Watson Pharma, being the first generic company to successfully challenge Prilosec’s patent, will also have exclusive marketing rights during the 180 day period.